These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 29143068

  • 1. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N.
    Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
    [Abstract] [Full Text] [Related]

  • 2. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Duangnapasatit B, Rattarittamrong E, Rattanathammethee T, Hantrakool S, Chai-Adisaksopha C, Tantiworawit A, Norasetthada L.
    Asian Pac J Cancer Prev; 2015 Jan; 16(12):5013-8. PubMed ID: 26163633
    [Abstract] [Full Text] [Related]

  • 3. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H.
    Acta Haematol; 2015 Jan; 133(1):36-51. PubMed ID: 25116092
    [Abstract] [Full Text] [Related]

  • 4. Analysis of clinical characteristics of bone marrow proliferative tumor progression to acute myeloid leukemia.
    Li Y, Zhang XY, Han J, Wang L.
    Cancer Biomark; 2018 Jan; 23(4):469-472. PubMed ID: 30452397
    [Abstract] [Full Text] [Related]

  • 5. [Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].
    Valladares X, Benavente R, Rojas C, Peña C, Valenzuela R, Monardes V, López H, Abarca M, León P, Osorio R, Pérez E, Soto P, Rocca G, Cardemil D, Torres V, Intriago M, Cabrera ME, Undurraga MS.
    Rev Med Chil; 2021 Nov; 149(11):1532-1538. PubMed ID: 35735314
    [Abstract] [Full Text] [Related]

  • 6. [Clinical and epidemiological characteristics of the Philadelphia negative myeloproliferative neoplasms in Chile].
    Valladares X, Benavente R, Rojas C, Peña C, Valenzuela R, Monardes V, López H, Abarca M, León P, Osorio R, Pérez E, Soto P, Rocca G, Cardemil D, Torres V, Intriago M, Cabrera ME, Undurraga MS.
    Rev Med Chil; 2021 Dec; 149(12):1687-1693. PubMed ID: 35735335
    [Abstract] [Full Text] [Related]

  • 7. Leukocytosis and MPNs: Where do we stand?
    Coltoff A.
    Leuk Lymphoma; 2023 Mar; 64(3):564-572. PubMed ID: 36519233
    [Abstract] [Full Text] [Related]

  • 8. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
    Deadmond MA, Smith-Gagen JA.
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
    [Abstract] [Full Text] [Related]

  • 9. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
    Landgren O, Goldin LR, Kristinsson SY, Helgadottir EA, Samuelsson J, Björkholm M.
    Blood; 2008 Sep 15; 112(6):2199-204. PubMed ID: 18451307
    [Abstract] [Full Text] [Related]

  • 10. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
    Lim Y, Lee JO, Bang SM.
    J Korean Med Sci; 2016 Oct 15; 31(10):1579-85. PubMed ID: 27550486
    [Abstract] [Full Text] [Related]

  • 11. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
    Shallis RM, Zeidan AM, Wang R, Podoltsev NA.
    Hematol Oncol Clin North Am; 2021 Apr 15; 35(2):177-189. PubMed ID: 33641862
    [Abstract] [Full Text] [Related]

  • 12. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
    Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Vannucchi AM, Passamonti F, Samuelsson J, Birgegard G, Mesa RA.
    Blood; 2014 Jun 12; 123(24):3803-10. PubMed ID: 24553173
    [Abstract] [Full Text] [Related]

  • 13. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
    Mesa RA, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Naim A, Parasuraman S, Boyle J, Mascarenhas JO.
    Cancer; 2017 Feb 01; 123(3):449-458. PubMed ID: 27690182
    [Abstract] [Full Text] [Related]

  • 14. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
    Cerquozzi S, Tefferi A.
    Blood Cancer J; 2015 Nov 13; 5(11):e366. PubMed ID: 26565403
    [Abstract] [Full Text] [Related]

  • 15. Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
    Mesa R, Jamieson C, Bhatia R, Deininger MW, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, Klisovic RB, Kropf P, Mohan SR, Oh S, Padron E, Podoltsev N, Pollyea DA, Rampal R, Rein LA, Scott B, Snyder DS, Stein BL, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H.
    J Natl Compr Canc Netw; 2016 Dec 13; 14(12):1572-1611. PubMed ID: 27956542
    [Abstract] [Full Text] [Related]

  • 16. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
    Mesa R, Miller CB, Thyne M, Mangan J, Goldberger S, Fazal S, Ma X, Wilson W, Paranagama DC, Dubinski DG, Boyle J, Mascarenhas JO.
    BMC Cancer; 2016 Feb 27; 16():167. PubMed ID: 26922064
    [Abstract] [Full Text] [Related]

  • 17. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
    Ouyang J, Zheng W, Shen Q, Goswami M, Jorgensen JL, Medeiros LJ, Wang SA.
    Cytometry B Clin Cytom; 2015 Feb 27; 88(4):236-43. PubMed ID: 25557358
    [Abstract] [Full Text] [Related]

  • 18. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
    Yassin MA, Taher A, Mathews V, Hou HA, Shamsi T, Tuğlular TF, Xiao Z, Kim SJ, Depei W, Li J, Rippin G, Sadek I, Siddiqui A, Wong RS.
    Cancer Med; 2020 Jul 27; 9(13):4512-4526. PubMed ID: 32351024
    [Abstract] [Full Text] [Related]

  • 19. [Clinical and genetic characteristics of young patients with myeloproliferative neoplasms].
    Zhang MY, Bao M, Shi DY, Shi HX, Liu XL, Xu N, Duan MH, Zhuang JL, Du X, Qin L, Hui WH, Liang R, Wang MF, Chen Y, Li DY, Yang W, Tang GS, Zhang WH, Kuang X, Su W, Han YQ, Chen LM, Xu JH, Liu ZG, Huang J, Zhao CT, Tong HY, Hu JD, Chen CY, Chen XQ, Xiao ZJ, Jiang Q.
    Zhonghua Xue Ye Xue Za Zhi; 2023 Mar 14; 44(3):193-201. PubMed ID: 37356980
    [Abstract] [Full Text] [Related]

  • 20. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
    Sankar K, Stein BL, Rampal RK.
    Cancer Treat Res; 2019 Mar 14; 179():159-178. PubMed ID: 31317487
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.